Akebia Therapeutics (AKBA) Other financing activities (2015 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Other financing activities of $20000.0 for Q1 2026, down 95.85% year-over-year from $482000.0 in Q1 2025, and down 86.84% quarter-over-quarter from $152000.0 in Q3 2025.
Akebia Therapeutics (AKBA) Other financing activities (2015 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Other financing activities for 11 consecutive years, with $20000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 95.85% year-over-year to $20000.0; the TTM figure through Mar 2026 stood at -$232000.0 (down 146.87% YoY), while the FY2025 annual figure was $230000.0, up 49.35% from the prior year.
- Other financing activities declined to $20000.0 in Q1 2026 per AKBA's latest filing, from $152000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $482000.0 in Q1 2025 and bottomed at -$404000.0 in Q2 2025.
- Historically, Other financing activities has averaged $58214.3 across 5 years, with a median of $17000.0 in 2024.
- On a YoY basis, Other financing activities climbed as much as 7700.0% in 2025 and fell as far as 2985.71% in 2025.
- Akebia Therapeutics' Other financing activities stood at $343000.0 in 2022, then tumbled by 99.71% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024, then soared by 15100.0% to $152000.0 in 2025, then sank by 86.84% to $20000.0 in 2026.
- Business Quant data shows AKBA's Other financing activities at $20000.0 in Q1 2026, $152000.0 in Q3 2025, and -$404000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20,000.00 |
| Mar 31, 2026 | 20,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Sep 30, 2025 | 152,000.00 |
| Jun 30, 2025 | -404,000.00 |
| Jun 30, 2025 | -404,000.00 |
| Mar 31, 2025 | 482,000.00 |
| Mar 31, 2025 | 482,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Sep 30, 2023 | -34,000.00 |